insights from advance iv study: efgartigimod increases platelet counts of patients with itp
Published 1 year ago • 158 plays • Length 0:52Download video MP4
Download video MP3
Similar videos
-
2:50
time to achieve platelet count response with efgartigimod in patients with persistent/chronic itp
-
5:45
advance iv results: efficacy and safety of intravenous efgartigimod in adults with primary itp
-
1:54
fostamatinib and efgartigimod: novel agents in the treatment of itp
-
4:14
long-term safety and efficacy of sutimlimab for chronic itp
-
3:40
final analysis of the phase 4 exels trial in high-risk patients with essential thrombocythemia
-
19:42
immune thrombocytopenia (itp) — most comprehensive explanation — hematology
-
17:40
is itp curable?
-
3:53
essential thrombocythemia watch & wait | what patients should know
-
2:15
5 facts about itp
-
1:26
improving the sensitivity of platelet autoantibody testing for itp diagnosis
-
2:41
an overview of the latest advances in hematology
-
1:05
hematological predictors of thrombotic risk or disease progression in essential thrombocythemia
-
1:24
recent advances in the treatment and management of itp
-
2:38
the management of itp during and after the covid-19 pandemic
-
0:45
difference between quality of life & patient-reported outcomes
-
25:29
key insights: real-world evidence for itp treatment
-
1:46
current treatment approaches in et and an insight into the surpass-et trial
-
1:30
recent advancements in bpdcn: diagnostic criteria, pathophysiology, and treatment
-
1:14
highlights in quality management from ebmt
-
3:56
results of the phase ii titan study of caplacizumab in patients with attp
-
11:10
bleeding disorders, part 2 - superficial bleed, primary platelet plug *usmle steps 1, 2 & 3*
-
4:48
an insight into the management of cytopenias in mf